Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.
Celularity has raised $10.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in September 2026.
Celularity's investors include Alumni Ventures, S32, Human Longevity, Heritage Group, United Therapeutics.
Celularity is headquartered in Florham Park, United States.
Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.
Celularity is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Celularity — Funding & Investors." VCBacked, September 24, 2026, https://www.vcbacked.co/company/celularity. Accessed November 16, 2026.
VCBacked. (2026). Celularity — Funding & Investors. Retrieved November 16, 2026, from https://www.vcbacked.co/company/celularity
{{cite web |title=Celularity — Funding & Investors |url=https://www.vcbacked.co/company/celularity |website=VCBacked |access-date=November 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Celularity? Request a listing update